Continuous AMR Partnering Initiative CAPI
The Continuous AMR Partnering Initiative CAPI addresses the high global demand for novel Technologies, Products and Services that contribute to the control of Antimicrobial Resistance (AMR). These include emerging antimicrobials, alternative antimicrobial therapies, microbial diagnostics, preventives and related products and services.
CAPI was established to make important academic discoveries that can contribute to the fight against AMR easy to find, understand and transfer.
CAPI was primarily set up to break the impasse in which valuable, promising and (un)published research ultimately remains on the shelf and does not contribute to the fight against AMR.
CAPI offers suppliers of emerging and existing Technologies, Products and Services (such as Academic and Research Institutions, startups and SMEs) the opportunity to bring these to the attention of users (such as Hospitals, Laboratories and Research Institutes, as well as Financiers, Start-Ups, SMEs, Multinationals, Authorities and NGOs). They can select the most relevant Technologies, Products and Services by using the newly developed, dedicated filters. Interested users then can directly and without the intervention of AMR Insights contact the supplier.
The Technology pages contain a clear explanation of Technology, Product or Service and may be illustrated with photos and a video. In addition to a hyperlink to the website of the supplier, the Technology page contains the supplier’s contact details.
Suppliers can create one or more Technology pages of their choice.
The proprietary Technology page(s) are visible to everyone worldwide and can easily be shared on social media.
CAPI is an initiative of AMR Insights and aims to increasingly add to the global curbing of AMR.